

DIN EN ISO 18562-1:2020-05 (E)

Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 1: Evaluation and testing within a risk management process (ISO 18562-1:2017)

Contents	Page
European foreword	3
Foreword	4
Introduction	5
1 Scope	7
2 Normative references	8
3 Terms and definitions	8
4 General principles applying to BIOCMPATIBILITY evaluation of MEDICAL DEVICES	12
4.1 General	12
4.2 TYPE TESTS	13
4.3 BIOCMPATIBILITY HAZARD identification	14
4.4 Extent of RISK ASSESSMENT	14
4.5 BIOCMPATIBILITY evaluation plan	15
4.6 Selection of tests	16
4.7 Subsequent evaluation	16
5 Contamination of breathing gas from GAS PATHWAYS	17
5.1 * Duration of use	17
5.2 PARTICULATE MATTER (PM) emissions	19
5.3 VOLATILE ORGANIC COMPOUND (VOC) emissions	19
5.4 LEACHABLE SUBSTANCES in condensate	19
6 Adjustment for different PATIENT groups	19
6.1 General considerations	19
6.2 Adjustment for body weight	19
6.3 * Deriving a permitted concentration from a TOLERABLE EXPOSURE	20
7 * Deriving allowable limits	20
7.1 General PROCESS	20
7.2 For MEDICAL DEVICES intended for limited exposure use (≤ 24 h)	21
7.3 For MEDICAL DEVICES intended for prolonged exposure use (> 24 h but < 30 d)	22
7.4 For MEDICAL DEVICES intended for permanent contact (≥ 30 d)	22
8 RISK benefit analysis	22
9 Assess the BIOCMPATIBILITY of the MEDICAL DEVICE	23
Annex A (informative) Rationale and guidance	24
Annex B (informative) Reference to the essential principles	26
Annex C (informative) Terminology — Alphabetized index of defined terms	27
Bibliography	29